Test Price
550 AEDโ Home Collection Available
CD23 Immunohistochemistry (IHC CD23) Test in UAE | 550 AED | DHA Licensed Diagnostic Pathology
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity
Processed via ISO 9001:2015 certified automated immunohistochemistry protocols. Hospital extraction only โ sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Secure Medical Courier Solid Tissue Specimen Retrieval ensures chain-of-custody integrity. Telephonic post-test clinical guidance available for result interpretation. Direct billing verification via WhatsApp +971 54 548 8731.
Turnaround Time: 5โ7 business days | Methodology: Automated IHC with anti-CD23 monoclonal antibodies | Specimen: Formalin-fixed paraffin-embedded (FFPE) tissue block or biopsy slide.
Test Overview & Methodology
The CD23 IHC test detects CD23 antigen expression in tissue sections using monoclonal antibodies, aiding the subclassification of B-cell lymphomas โ particularly chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma. The assay is performed on formalin-fixed paraffin-embedded (FFPE) tissue using an automated staining platform with standardized antigen retrieval and chromogenic detection. Results are reported as positive or negative with semi-quantitative assessment of staining intensity and percentage of reactive cells.
| Feature | Our CD23 IHC Test | Alternative (Flow Cytometry) |
|---|---|---|
| Diagnostic Precision | Morphological context with protein localization in tissue architecture | Quantitative antigen expression, limited tissue architecture |
| Methodology | Automated IHC with anti-CD23 monoclonal antibodies on FFPE tissue | Multiparametric flow cytometry on fresh/fixed cell suspensions |
| Turnaround Time | 5โ7 business days | 1โ2 business days |
| Specimen Requirement | FFPE tissue block, biopsy slide, or section (paraffin-embedded) | Fresh, unfixed tissue or fluid in transport medium |
Physician Insight & Safety Protocols
"In my practice, I observe that CD23 IHC results complement radiological and morphological assessments in lymphoma diagnosis. The antigen expression patterns revealed by this test help confirm diagnoses suggested by imaging, particularly in differentiating CLL/SLL from other B-cell neoplasms. However, these findings must always be interpreted alongside the complete clinical picture, imaging studies, and histopathological evaluation. No single test dictates therapy โ always integrate with the full diagnostic context."
โ Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication Advisory
Do not discontinue or alter any prescribed medication without consulting your treating physician. This diagnostic test does not replace clinical judgment or ongoing therapeutic monitoring.
Exclusion Criteria & Emergency Red Flags
- Patient must have a formalin-fixed paraffin-embedded (FFPE) tissue block, biopsy slide, or adequate surgical pathology specimen; insufficient tissue may preclude testing.
- Individuals with known severe bleeding disorders must have biopsy performed under controlled clinical settings โ not via standard outpatient collection.
- Seek immediate emergency care if you experience excessive bleeding, fever >38ยฐC, or sudden pain at the biopsy site within 48 hours post-procedure.
- This test is not a standalone diagnostic tool; always interpret with histopathology, imaging, and clinical correlation under specialist supervision.
Patient FAQ & Clinical Guidance
1. What is the CD23 IHC test used for?
The CD23 IHC test uses monoclonal antibodies to visualize CD23 protein expression in tissue sections. It is primarily employed to subclassify B-cell lymphomas, most commonly distinguishing chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) from mantle cell lymphoma and other CD23-negative B-cell neoplasms. The result is reported as positive or negative with documentation of staining intensity and percentage of reactive cells. Correlation with morphology, immunophenotype, and clinical findings is essential for accurate diagnosis.
2. How should I prepare for the test?
If an existing FFPE tissue block or biopsy slide is available, no additional preparation is required. If a new tissue biopsy is needed, your physician will provide specific pre-procedure instructions including informed consent and bleeding risk assessment. Our secure medical courier service transports the formalin-fixed specimen under temperature-controlled conditions to preserve antigen integrity.
3. How do I interpret my CD23 IHC result?
A positive CD23 result indicates expression of CD23 protein on lymphoma cells, a pattern characteristic of CLL/SLL. A negative result may support mantle cell lymphoma, follicular lymphoma, or other CD23-negative B-cell lymphomas. Results must be interpreted by your oncologist or hematopathologist alongside the full histopathology report, imaging findings, and clinical context. Our telephonic post-test guidance can help you understand your report, but does not replace specialist consultation.
UAE Regulatory & Data Privacy Adherence
All diagnostic procedures at DNA Labs UAE comply with the regulatory framework of the Dubai Health Authority (DHA) and UAE federal laws governing health data and medical practice. Patient information is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed under Federal Decree-Law No. 4 of 2016 on Medical Liability. Your data is encrypted, access-controlled, and used solely for diagnostic and quality assurance purposes.
Clinical & Logistical Metadata
| Test Name | CD23 Immunohistochemistry (IHC CD23) |
| Price (AED) | 550 AED |
| Turnaround Time | 5โ7 business days |
| Sample Type / Matrix | Formalin-fixed paraffin-embedded (FFPE) tissue block, biopsy slide, or tissue section |
| Methodology Used | Automated Immunohistochemistry (IHC) with anti-CD23 monoclonal antibodies, polymer detection system, and chromogenic visualization |
| ICD-10-CM Code | C91.1 (Chronic lymphocytic leukemia of B-cell type), C83.0 (Small cell B-cell lymphoma) |
| LOINC Code | 71633-7 (CD23 Ag [Presence] in Tissue by Immune stain) |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians